Compare SFST & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | RGNX |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.7M | 418.1M |
| IPO Year | 2012 | 2015 |
| Metric | SFST | RGNX |
|---|---|---|
| Price | $58.07 | $8.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $64.00 | $28.75 |
| AVG Volume (30 Days) | 99.1K | ★ 560.1K |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | 18.08 |
| EPS | ★ 3.72 | N/A |
| Revenue | $6,282,000.00 | ★ $10,393,000.00 |
| Revenue This Year | $10.47 | $50.15 |
| Revenue Next Year | $12.19 | $23.42 |
| P/E Ratio | $15.70 | ★ N/A |
| Revenue Growth | 12.99 | ★ 126.48 |
| 52 Week Low | $30.68 | $5.85 |
| 52 Week High | $62.00 | $16.19 |
| Indicator | SFST | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 64.50 | 53.88 |
| Support Level | $50.36 | $7.76 |
| Resistance Level | $58.77 | $9.28 |
| Average True Range (ATR) | 1.61 | 0.52 |
| MACD | 0.67 | 0.15 |
| Stochastic Oscillator | 82.20 | 84.57 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.